Kentucky Retirement Systems Acquires Shares of 8,794 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Kentucky Retirement Systems acquired a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm acquired 8,794 shares of the biopharmaceutical company's stock, valued at approximately $2,375,000.

Other large investors also recently modified their holdings of the company. Truist Financial Corp increased its stake in Alnylam Pharmaceuticals by 136.6% in the 4th quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company's stock worth $1,035,000 after buying an additional 2,539 shares in the last quarter. IFP Advisors Inc boosted its stake in shares of Alnylam Pharmaceuticals by 24.2% in the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock worth $57,000 after acquiring an additional 47 shares during the period. Brighton Jones LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $243,000. Silvercrest Asset Management Group LLC bought a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at approximately $1,151,000. Finally, New York State Teachers Retirement System raised its stake in Alnylam Pharmaceuticals by 10.5% during the 4th quarter. New York State Teachers Retirement System now owns 5,836 shares of the biopharmaceutical company's stock valued at $1,373,000 after purchasing an additional 553 shares during the period. Hedge funds and other institutional investors own 92.97% of the company's stock.

Analyst Ratings Changes

A number of brokerages have issued reports on ALNY. Wells Fargo & Company increased their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an "equal weight" rating in a report on Friday, March 21st. Wall Street Zen lowered shares of Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, June 14th. HC Wainwright reaffirmed a "buy" rating and set a $500.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 2nd. Scotiabank lifted their price target on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a "sector outperform" rating in a report on Monday, March 31st. Finally, Chardan Capital increased their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the company a "buy" rating in a report on Friday, May 2nd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have given a buy rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $324.83.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 19,297 shares of the company's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total value of $5,904,882.00. Following the transaction, the chief executive officer now owns 48,948 shares of the company's stock, valued at $14,978,088. This represents a 28.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Trading Down 0.9%

ALNY traded down $3.06 during trading on Wednesday, reaching $321.94. The company had a trading volume of 632,571 shares, compared to its average volume of 879,749. The company has a quick ratio of 2.98, a current ratio of 3.04 and a debt-to-equity ratio of 8.88. The business has a 50 day simple moving average of $282.80 and a 200-day simple moving average of $262.36. The stock has a market cap of $41.98 billion, a P/E ratio of -154.04 and a beta of 0.22. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $326.03.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The firm had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. During the same quarter last year, the business posted ($0.16) EPS. Alnylam Pharmaceuticals's revenue was up 20.2% compared to the same quarter last year. On average, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.